Genisphere Awarded Patent for Cellular Delivery of siRNA and other Therapeutics using 3DNA® Nanocarrier

HATFIELD, Pa., Dec. 10, 2015 /PRNewswire/ -- Genisphere LLC, provider of the 3DNA^® nanotechnology platform, reported today it has been granted a patent titled "DNA dendrimers protected against nuclease degradation are useful as vectors for the delivery of siRNA" from the European Patent Office. The patent includes claims for keeping the company's DNA-based therapeutic nanocarrier (trademarked 3DNA^®) intact in a living system. Physical protection of siRNA and other drug cargo is also claimed in the patent, when these therapeutic molecules are delivered using the 3DNA^® nanocarrier. This patent is part of Genisphere's "Long-acting DNA dendrimers and methods thereof" patent family which has issued composition of matter and methods claims covering a broad range of 3DNA^®-based pharmaceutical compositions.

Based on the granted claims, Genisphere's coverage includes a variety of strategies to shield its 3DNA^® from the harsh physiological environment often found in body fluids and tissues, as well as multiple approaches to attach siRNA to 3DNA^® while maximizing the complex's ability to achieve the biological outcome. The patent extends coverage to other drug payloads, including DNA molecules, proteins, chemotherapeutics, antivirals, and hormones.   

Tom Bliss, Genisphere's Chief Executive Officer, said "This patent and overall patent family is a significant component of Genisphere's extensive intellectual property portfolio, since our nanocarrier is broadly adaptable to deliver a variety of active pharmaceutical ingredients. Our pharma partners will benefit from this protection when their drug is formulated with our delivery technology, and ultimately the patent life of their drug will be extended." 

About Genisphere 
Genisphere LLC is the provider of the 3DNA^® platform for targeted drug delivery. 3DNA^® is a nanoscale, multivalent scaffold made from proprietary, synthetic DNA formed in a flexible, branched structure. 3DNA^® nanocarriers are engineered and cross-linked to form a stable architecture while maintaining the biocompatibility of the nucleic-acid building blocks, and demonstrate efficacy and safety with a variety of drug cargos across multiple indications. Genisphere's technology is IP-protected and fully customizable to deliver small molecules, biologics, and nucleic acids with precise specificity enabled by multivalent targeting via antibodies, peptides and other molecular entities. Genisphere leverages a collaborative model to advance its 3DNA^® drug delivery platform, and seeks additional partnerships with biotechnology and pharmaceutical companies to improve efficacy and reduce toxicity. Genisphere is also advancing its own lead compounds based on 3DNA^® nanotechnology. For more information, please visit http://genisphere.com

For more information contact:

Tom Bliss 
Genisphere   
215-996-3027 
Email

SOURCE Genisphere LLC